Tiziana Life Sciences‘ intranasal spray foralumab continues to be safe and well-tolerated, with no drug-related serious side effects reported after long-term use, according to an annual report filed with the U.S. Food and Drug Administration (FDA). The company is developing foralumab for neuroinflammatory diseases such as multiple sclerosis (MS), Alzheimer’s disease, and multiple system atrophy. […]
The post Foralumab nasal spray continues to show long-term safety in SPMS: Data appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com